Neuphoria Therapeutics Inc (NEUP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.77-7.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NEUP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenues | — | 1.2 | 15.6 | — | — | — |
| Total Revenues | — | 1.2 | — | — | — | — |
| Operating Expenses & Income | ||||||
| R&D Expenses | — | — | 9.0 | 9.4 | 13.1 | — |
| Operating Income | (16.5) | (16.5) | (1.1) | (17.9) | (22.0) | — |
| Earnings from Continuing Operations | ||||||
| Interest & Investment Income | 0.7 | 0.7 | 0.2 | 0.2 | 0.3 | — |
| Other Non-Operating Income / Expenses | 2.9 | 2.9 | 0.3 | 2.3 | 0.5 | — |
| EBT, Incl. Unusual Items | (13.6) | (13.6) | (0.8) | (15.6) | (21.5) | — |
| Income Tax Expense | (0.1) | (0.1) | (0.5) | (0.1) | (0.1) | — |
| Net Income | ||||||
| Net Income | (13.5) | (13.5) | (0.4) | (15.5) | (21.4) | — |
| Per Share | ||||||
| Basic EPS | — | (3.06) | (0.23) | (0.01) | (0.02) | — |
| Diluted EPS | — | (3.06) | (0.23) | (0.01) | (0.02) | — |
| Basic Weighted Avg Shares | — | 4.4 | 1.6 | 1,797.6 | 1,468.7 | — |
| Diluted Weighted Avg Shares | — | 4.4 | 1.6 | 1,797.6 | 1,468.7 | — |
| Supplemental | ||||||
| EBITDA | — | (15.8) | (0.5) | (17.2) | (21.3) | — |
| EBIT | (16.5) | (16.5) | (1.1) | (17.9) | (22.0) | — |
| Effective Tax Rate | 1.0% | — | — | — | 0.6% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.